Emily Chudy's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q2 2025
Question
Emily Chudy of Stifel Financial Corp. inquired about the anticipated timeline for an NDA filing following the top-line data for focal onset seizures (FOS) and sought reassurance on how Xenon would avoid safety issues with its Nav1.7 pain program, which have affected similar mechanisms in the past.
Answer
President and CEO Ian Mortimer stated that an NDA filing is expected approximately six months after the top-line data readout. Regarding the Nav1.7 program, he expressed confidence that Xenon has addressed potential cardiovascular risks seen in earlier drugs through its molecule's specific profile and noted the absence of any such signals in preclinical safety data.